Novo Nordisk Advances Next-Gen Obesity Treatments with LX9851 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy NVO?
Source: stocktwits
- Clinical Trial Initiation: Novo Nordisk has announced the initiation of a Phase 1 study for LX9851, an oral non-incretin drug candidate from Lexicon Pharmaceuticals aimed at treating obesity and related metabolic disorders, marking a significant advancement in the company's obesity treatment efforts.
- Milestone Payment Triggered: The start of this trial triggers a second $10 million milestone payment to Lexicon under their licensing agreement signed in March 2025, granting Novo Nordisk exclusive global rights to develop and commercialize the drug, with Lexicon eligible for up to $1 billion in total milestone payments and royalties on future sales.
- Trial Scale and Timeline: The Phase 1 study will evaluate safety and dosing in 96 overweight or obese participants, expected to be completed by early 2027, demonstrating Novo Nordisk's commitment and strategic planning in advancing its drug pipeline.
- Market Reaction and Outlook: While NVO shares fell 1.5%, LXRX's stock rose about 1% in pre-market trading, reflecting market optimism regarding the new drug development and enhancing Novo Nordisk's competitive position in the obesity treatment market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 46.400
Low
42.00
Averages
54.67
High
70.00
Current: 46.400
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's High-Dose Wegovy Shows Significant Weight Loss Results
- Early Responders Performance: Among patients receiving the 7.2 mg Wegovy, approximately 27% of early responders lost nearly 28% of their body weight over 72 weeks, compared to about 25% in the 2.4 mg group, highlighting the significant advantage of the higher dose.
- Faster Goal Achievement: Patients on the 7.2 mg dose achieved a 21% weight loss over 72 weeks, compared to 17.5% in the 2.4 mg group and 2% in the placebo group, indicating that the higher dose facilitates quicker weight loss goal attainment.
- Safety and Tolerability: In a trial involving over 1,400 obese adults without type 2 diabetes, the 7.2 mg semaglutide demonstrated a safety and tolerability profile consistent with the lower dose, further enhancing its potential as a long-term weight management therapy.
- Regulatory Approval Context: The earlier approval of the high-dose version by U.S. and EU regulators as a weight loss treatment underscores market recognition of its efficacy, potentially driving Novo Nordisk's market share growth in obesity treatment.
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Novo Nordisk's New Data Boosts Weight Loss Drug Market
- Significant New Dose Effects: Novo Nordisk's new data presented at the European Congress on Obesity indicates that patients using the 7.2 mg high-dose Wegovy lost an average of 27.7% of their weight over 72 weeks, showcasing the drug's potential in weight loss treatment, which may attract more prescribers and patients.
- Intensified Market Competition: The weight loss efficacy of high-dose Wegovy is comparable to Eli Lilly's Zepbound, both exceeding 20%, positioning Novo to potentially regain market share, especially as Zepbound has become the preferred obesity drug.
- Early Responders Analysis: In the trial, about one in four high-dose patients exhibited early treatment responses, losing over 15% of their weight, compared to one in five for the 2.4 mg dose, highlighting the potential advantages of the higher dosage.
- Market Dynamics Uncertainty: Despite the encouraging new data, analysts caution that it remains unclear whether high-dose Wegovy will significantly alter the market share dynamics between Novo and Lilly, as Zepbound's entrenched position in the market persists.
See More
Hims & Hers Reports Q1 Loss and Weak Guidance
- Financial Decline: Hims & Hers reported a net loss of $92 million in Q1, significantly worsening from a $50 million loss in the same period last year, indicating severe challenges in profitability.
- Adjusted EBITDA Drop: The company's adjusted EBITDA fell from $91 million last year to $44 million, reflecting declining operational efficiency and increasing cost pressures, which may undermine investor confidence moving forward.
- Weak Revenue Growth: Although revenue increased by 4% to $608 million, the average monthly revenue per subscriber decreased from $85 to $80, suggesting weakened consumer spending willingness that could impact long-term growth potential.
- Poor Outlook: Hims expects Q2 revenue between $680 million and $700 million, with a full-year forecast of up to $3 billion, but analysts believe this guidance falls short of market expectations, potentially leading to further stock price declines.
See More
Novo Nordisk's Wegovy Data Shows Significant Weight Loss Improvements
- Significant Weight Loss Results: Novo Nordisk's study reveals that patients taking the 7.2 mg Wegovy lost an average of 27.7% of their body weight over 72 weeks, demonstrating faster weight loss compared to the standard 2.4 mg dose, thereby enhancing the company's competitive edge in the obesity drug market.
- Fat Reduction with Muscle Preservation: The data indicates that 84% of the weight loss was due to reductions in body fat while muscle strength and health were largely preserved, suggesting that Wegovy effectively protects muscle health during weight loss, increasing the drug's appeal.
- Intensifying Market Competition: Following the release of new data, Novo's shares rose 3% in premarket trading, reflecting increased market confidence in its obesity drug, particularly as it seeks to narrow the gap with Eli Lilly in the competitive landscape.
- New Drug Rollout and Regulatory Progress: Novo has launched the higher-dose Wegovy in the U.S. and is seeking approval for a single-dose 7.2 mg pen in Europe and the U.K., which is expected to further expand its market share and meet the growing demand for obesity treatments.
See More
Novo Nordisk's High-Dose Wegovy Shows Significant Weight Loss Results
- Early Responders Performance: Among patients receiving the 7.2 mg Wegovy, approximately 27% of early responders lost nearly 28% of their body weight over 72 weeks, compared to about 25% in the 2.4 mg group, highlighting the significant advantage of the higher dose.
- Faster Goal Achievement: Patients on the 7.2 mg dose achieved a 21% weight loss over 72 weeks, compared to 17.5% in the 2.4 mg group and 2% in the placebo group, indicating that the higher dose facilitates quicker weight loss goal attainment.
- Safety and Tolerability: In a trial involving over 1,400 obese adults without type 2 diabetes, the 7.2 mg semaglutide demonstrated a safety and tolerability profile consistent with the lower dose, further enhancing its potential as a long-term weight management therapy.
- Regulatory Approval Context: The earlier approval of the high-dose version by U.S. and EU regulators as a weight loss treatment underscores market recognition of its efficacy, potentially driving Novo Nordisk's market share growth in obesity treatment.
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong market demand and investment opportunities.
- Technology Innovation Showcase: VentriPoint will present its VMS+™ 4.0 platform at the AEPC annual meeting in Padua, Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI and significantly enhancing clinical diagnostic efficiency.
- International Expansion and Collaboration: VentriPoint has partnered with Lishman Global to submit VMS+™ 4.0 for approval to China's National Medical Products Administration, utilizing the expedited
See More
VentriPoint Diagnostics Showcases AI Cardiac Imaging Platform at Major Conference
- Market Growth Potential: The global point-of-care diagnostics market reached $58.76 billion in 2026, growing nearly 10% annually, with projections to hit $114.65 billion by 2035, indicating strong demand for rapid and convenient healthcare solutions that create significant opportunities for companies like VentriPoint.
- Showcase Opportunity: VentriPoint will present its AI-powered VMS+™ 4.0 cardiac imaging platform at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology in Padua, Italy, expected to attract over 1,000 cardiology specialists from 32 countries, enhancing brand visibility and market penetration.
- Regulatory Expansion Progress: VentriPoint's strategic partner Lishman Global has formally submitted VMS+™ 4.0 for approval to China's National Medical Products Administration, leveraging the expedited
See More
Novo Nordisk's New Data Boosts Weight Loss Drug Market
- Significant New Dose Effects: Novo Nordisk's new data presented at the European Congress on Obesity indicates that patients using the 7.2 mg high-dose Wegovy lost an average of 27.7% of their weight over 72 weeks, showcasing the drug's potential in weight loss treatment, which may attract more prescribers and patients.
- Intensified Market Competition: The weight loss efficacy of high-dose Wegovy is comparable to Eli Lilly's Zepbound, both exceeding 20%, positioning Novo to potentially regain market share, especially as Zepbound has become the preferred obesity drug.
- Early Responders Analysis: In the trial, about one in four high-dose patients exhibited early treatment responses, losing over 15% of their weight, compared to one in five for the 2.4 mg dose, highlighting the potential advantages of the higher dosage.
- Market Dynamics Uncertainty: Despite the encouraging new data, analysts caution that it remains unclear whether high-dose Wegovy will significantly alter the market share dynamics between Novo and Lilly, as Zepbound's entrenched position in the market persists.
See More
Hims & Hers Reports Q1 Loss and Weak Guidance
- Financial Decline: Hims & Hers reported a net loss of $92 million in Q1, significantly worsening from a $50 million loss in the same period last year, indicating severe challenges in profitability.
- Adjusted EBITDA Drop: The company's adjusted EBITDA fell from $91 million last year to $44 million, reflecting declining operational efficiency and increasing cost pressures, which may undermine investor confidence moving forward.
- Weak Revenue Growth: Although revenue increased by 4% to $608 million, the average monthly revenue per subscriber decreased from $85 to $80, suggesting weakened consumer spending willingness that could impact long-term growth potential.
- Poor Outlook: Hims expects Q2 revenue between $680 million and $700 million, with a full-year forecast of up to $3 billion, but analysts believe this guidance falls short of market expectations, potentially leading to further stock price declines.
See More
Novo Nordisk's Wegovy Data Shows Significant Weight Loss Improvements
- Significant Weight Loss Results: Novo Nordisk's study reveals that patients taking the 7.2 mg Wegovy lost an average of 27.7% of their body weight over 72 weeks, demonstrating faster weight loss compared to the standard 2.4 mg dose, thereby enhancing the company's competitive edge in the obesity drug market.
- Fat Reduction with Muscle Preservation: The data indicates that 84% of the weight loss was due to reductions in body fat while muscle strength and health were largely preserved, suggesting that Wegovy effectively protects muscle health during weight loss, increasing the drug's appeal.
- Intensifying Market Competition: Following the release of new data, Novo's shares rose 3% in premarket trading, reflecting increased market confidence in its obesity drug, particularly as it seeks to narrow the gap with Eli Lilly in the competitive landscape.
- New Drug Rollout and Regulatory Progress: Novo has launched the higher-dose Wegovy in the U.S. and is seeking approval for a single-dose 7.2 mg pen in Europe and the U.K., which is expected to further expand its market share and meet the growing demand for obesity treatments.
See More
